Los Angeles, USA, April 20, 2021 (GLOBE NEWSWIRE) -- Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight
More than 50% of trials investigating CAR-T therapies for different indications are underway in the US, with around 80% of the trials for Haematological tumours.
DelveInsight’s “CAR-T Pipeline Insight” report offers a broad view of available CAR-T therapies in the market, pipeline CAR-T therapies, their MoA, RoA, key companies working in the domain, and competitive assessment.
The report analyzes over 60 molecules in Phase I/II, ~100 molecules in Phase I, ~150 molecules in Preclinical, and ~40 molecules in the Discovery stage for different indications.
Some of the key takeaways from the CAR-T Pipeline Insights Report:
- The CAR-T therapy pipeline report offers an analysis of over 250 key companies and 250+ CAR-T therapies in different stages of clinical development.
- At present, more than 300 clinical trials of CAR-T cell therapies have been approved by several national drug regulatory agencies, including the US FDA.
- Key companies developing CAR-T therapies include AbbVie Inc., Adaptimmune Therapeutics PLC., Amgen, Inc., Atara Biotherapeutics, Inc., Aurora Biopharma, Inc., Autolus Therapeutics PLC., Bellicum Pharmaceuticals, Inc., BioAtla LLC., bluebird bio, Carina Biotech, CARsgen Therapeutics, Ltd., CARTherics, Celgene, Cellectis, Celularity, Celyad SA, Creative Biolabs, DiaCarta, Inc., Endocyte, Inc., F1 Oncology, Inc., Fate Therapeutics Inc., Gilead, Humanigen, Inc., Immune Therapeutics, Inc., Intrexon, Corp., Juno Therapeutics, Inc., Kite Pharma, Inc., Lion TCR Pte Ltd., MaxCyte, Inc., Mesoblast, Ltd., Minerva Biotechnologies Corp., Mustang Bio, Inc., Novartis AG, Oxford BioMedica PLC., PeproMene Bio Inc., Pfizer, Inc., Posedia Therapeutics Inc., Precision Biosciences, Inc., ProMab Biotechnologies Inc., Servier Oncology, Sorrento Therapeutics, Inc., TC Biopharm Ltd., Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Tmunity Therapeutics Inc., TrakCel Ltd., Xyphos, ZIOPHARM Oncology, Inc., and others.
- The companies with their CAR-T drug candidates in the most advanced stage, i.e. phase III include, Janssen Research & Development, ViiV Healthcare, Sorrento Therapeutics, Celgene, Novartis, and Abbott.
- Key CAR-T therapies in different stages of development include LCAR-B38M CAR-T Cell, Anti-CEA CAR-T cells, CD30.CAR-T, AUTO CAR T cell therapy, Defibrotide, MB-CART2019.1 Dose level 1, CAR-T, CD19/22 CART, JNJ-68284528, CD123 CAR-T cells, CD19 CAR-T cells, BCMA CAR-T cells, CEA CAR-T cells, CAR-T cell immunotherapy, Autologous CAR-T cells, Second generation CAR-T cells, CAR-T/TCR-T cells immunotherapy, Allogeneic hematological stem cell transplantation, Humanized CD19 CAR-T cells, CD19 CART, MB-CART20.1, MB-CART19.1, IM19 CAR-T Cells, CLDN6 CAR-T, Autologous CD19-targeting CAR T cells, P-BCMA-101 CAR-T cells, MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3, CART-19/22, Anakinra, Anti-MUC1 CAR-T cells, CAR T-cell therapy, CAR T cells, CART-19, CAR-CD19 T Cells, CAR-BCMA T Cells, LCAR-B38M CAR-T cell injection, AUTO1, AUTO3, Gene-modified (GM) T cell therapy, Descartes-08, iC9-CAR19 cells, ALLO-501A, and others.
Interested in knowing more? Request for the sample @ CAR-T Cell Therapies Pipeline Analysis
The report underlines the present unmet needs in the market, driving factors, and market constraints, along with the holistic view of the inactive therapeutics (comprising dormant and terminated products) with the reasons behind their downfall, detailed insights into the structure and gene editing tool of the pipeline CAR-T cell therapies to help clients gauge the opportunities and risks in the market.
In the News
- In March 2021, Actinium Pharmaceuticals announced the initiation of patient enrolment in the Phase I study of Iomab-ACT for targeted conditioning before treatment with Memorial Sloan Kettering Cancer Center’s (MSK) CD19 targeted CAR T-cell 19-28z.
- In February 2021, AbbVie signed a collaboration and licensing agreement with Caribou Biosciences for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.
- In January 2021, Tessa Therapeutics announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
Interested in knowing more? Request for the sample @ CAR-T Pipeline Therapies
At a Glance: Emerging CAR-T Therapies, RoA, MoA and Companies
| Drug | Company | Clinical Phase | Target Indication | RoA |
| bb21217 | Bluebird Bio/ Celgene | Phase I | Multiple myeloma | Intravenous |
| UCART123 | Cellectis | Phase I | Acute Myeloid Leukemia (AML) | NA |
| Descartes-11 | Cartesian Therapeutics | Phase II | Multiple Myeloma | NA |
| CTL119 | Novartis | Phase II | Acute Lymphoid Leukemia, Multiple Myeloma | Infusion |
| AUTO5 | Autolus | Preclinical | T-cell lymphoma | NA |
| AUTO3 | Autolus | Phase I/II | Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Intravenous |
| CT053 | Carsgen Therapeutics | Phase I/II | Multiple Myeloma | Intravenous |
| CTL119 | Novartis | Phase II | Acute Lymphoid Leukemia, Multiple Myeloma | NA |
| TT11 | Tessa Therapeutics | Phase II | Hodgkin's Lymphoma, Non-Hodgkin Lymphoma | Infusion |
| MB-102 | Mustang Bio | Phase I/II | Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | Intravenous |
| CEA CAR T | Sorrento Therapeutics | Phase II/III | Malignant Tumor of Pancreas Metastatic to Liver | Intrahepatic |
| CNCT19 | CASI Pharmaceuticals/ Juventas Cell Therapy | Phase II | Non-Hodgkin's Lymphoma, Relapsed or Refractory Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Relapsed or Refractory Hematological Malignancies | Intravenous |
| Descartes-11 | Cartesian Therapeutics | Phase II | Multiple Myeloma | NA |
Know more about budding CAR-T therapies projected to transform the landscape @ Emerging CAR-T Therapeutics and Market Scenario
CAR-T Therapeutic Assessment
The CAR-T Therapies Pipeline report proffers comprehensive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Intrahepatic
- Intravenous
- Intratumoral
- Intraventricular
- Intraperitoneal
- Intracavitary
- Parenteral
By Mechanism of Action
- Anti-CEA CAR T-cell immunotherapy
- Anti-BCMA chimeric antigen receptor T-cell immunotherapy
- CD19-targeted chimeric antigen receptor T-cell immunotherapy
By Targets
- CEA
- BCMA
- CD19
By Stage and Route of Administration
By Stage and Product Type
To know more, Visit CAR-T Pipeline and Emerging Trends
Scope of the report
- Coverage: Global
- Key Players: AbbVie Inc., Adaptimmune Therapeutics PLC., Amgen, Inc., Atara Biotherapeutics, Inc., Aurora Biopharma, Inc., Autolus Therapeutics PLC., Bellicum Pharmaceuticals, Inc., BioAtla LLC., bluebird bio, Carina Biotech, CARsgen Therapeutics, Ltd., CARTherics, Celgene, Cellectis, Celularity, Celyad SA, Creative Biolabs, DiaCarta, Inc., Endocyte, Inc., F1 Oncology, Inc., Fate Therapeutics Inc., Gilead, Humanigen, Inc., Immune Therapeutics, Inc., Intrexon, Corp., Juno Therapeutics, Inc., Kite Pharma, Inc., Lion TCR Pte Ltd., MaxCyte, Inc., Mesoblast, Ltd., Minerva Biotechnologies Corp., Mustang Bio, Inc., Novartis AG, Oxford BioMedica PLC., PeproMene Bio Inc., Pfizer, Inc., Posedia Therapeutics Inc., Precision Biosciences, Inc., ProMab Biotechnologies Inc., Servier Oncology, Sorrento Therapeutics, Inc., TC Biopharm Ltd., Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Tmunity Therapeutics Inc., TrakCel Ltd., Xyphos, ZIOPHARM Oncology, Inc., and others.
- Key CAR-T Pipeline Therapies: LCAR-B38M CAR-T Cell, Anti-CEA CAR-T cells, CD30.CAR-T, AUTO CAR T cell therapy, Defibrotide, MB-CART2019.1 Dose level 1, CAR-T, CD19/22 CART, JNJ-68284528, CD123 CAR-T cells, CD19 CAR-T cells, BCMA CAR-T cells, CEA CAR-T cells, CAR-T cell immunotherapy, Autologous CAR-T cells, Second generation CAR-T cells, CAR-T/TCR-T cells immunotherapy, Allogeneic hematological stem cell transplantation, Humanized CD19 CAR-T cells, CD19 CART, MB-CART20.1, MB-CART19.1, IM19 CAR-T Cells, CLDN6 CAR-T, Autologous CD19-targeting CAR T cells, P-BCMA-101 CAR-T cells, MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3, CART-19/22, Anakinra, Anti-MUC1 CAR-T cells, CAR T-cell therapy, CAR T cells, CART-19, CAR-CD19 T Cells, CAR-BCMA T Cells, LCAR-B38M CAR-T cell injection, AUTO1, AUTO3, Gene-modified (GM) T cell therapy, Descartes-08, iC9-CAR19 cells, ALLO-501A, and others.
Want to learn more about the leading candidates in different clinical stages of trials? Reach out @ CAR-T Emerging Therapies and Key Companies
Key Questions Answered in the Report
- How many companies are developing CAR-T drugs?
- How many CAR-T drugs are developed by each company?
- How many emerging drugs are in the mid-stage, and late-stage of development for the treatment of CAR-T?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR-T therapeutics?
- What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR-T and their status?
- What are the key designations that have been granted to the emerging drugs?
Got queries? Get in touch @ CAR-T Pipeline Therapies, and Clinical Trial Analysis
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | CAR-T Therapies Overview |
| 4 | CAR-T Therapies Pipeline Scenario |
| 5 | CAR-T Therapies Pipeline Therapeutics |
| 6 | CAR-T Therapies Preclinical Stage Products |
| 7 | In-depth Commercial CAR-T Therapeutics Assessment |
| 8 | Late Stage CAR-T Pipeline Products (Phase III and Preregistration) |
| 9 | Mid-Stage CAR-T Pipeline Products (Phase II) |
| 10 | Pre-clinical and Discovery Stage CAR-T Pipeline Therapies |
| 11 | Inactive CAR-T Pipeline Products |
| 12 | CAR-T Key Companies |
| 13 | CAR-T Key Products |
| 14 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 15 | CAR-T Market Drivers and Barriers |
| 16 | CAR-T Future Perspectives and Conclusion |
| 17 | CAR-T Pipeline Therapies: Analyst Views |
| 18 | Appendix |
Know more about the report offerings @ CAR-T Therapies, and Upcoming Trends
Related Reports
CAR-T Cell Therapy For Acute Lymphoblastic Leukemia Market
DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030” report.
CAR-T Cell Therapy For Multiple Myeloma Market
DelveInsight’s ‘CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030’ report.
CAR-T Cell Therapy For Non-Hodgkin's Lymphoma Market
DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) - Market Insights and Market Forecast-2030’ report.
CAR-T Cell Immunotherapy Competitive Landscape Pipeline And Market Analysis
“Chimeric Antigen Receptor T Cells - Competitive Landscape, Pipeline and Market Analysis, 2021” report.
Adeno Associated Virus Vectors In Gene Therapy Market
DelveInsight's "Adeno-Associated Virus Vectors in Gene Therapy - Market Insights, Epidemiology, and Market Forecast-2030" report.
Gene Therapy In Oncology Innovation To Commercialization Competitive Landscape
DelveInsight “Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions, 2018” report.
Calcitonin Gene-Related Peptide Receptor Antagonist Pipeline Insight
DelveInsight, “Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists – Pipeline Insights, 2021” report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.